According to KEYNOTE-048, response to pembrolizumab monotherapy or added to platinum-based chemotherapy in first-line chemotherapy for recurrent and/or metastatic (R/M) HNSCC without curative treatment option was superior in patients with tumors expressing PD-L1 (CPS ≥ 1) and increased their survival (6). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.